[Leu5]enkephalin-like immunoreactive amacrine cells are under nicotinic excitatory control during darkness in chicken retina.
Based on the principle that retinal levels of [Leu5]enkephalin-like immunoreactivity (LELI) are set by the rate of release and thus reflect neural activity, we partially defined the dark-associated increase in excitatory control of LELI amacrine cells in chicken. Retinal levels of LELI were measured by radioimmunoassay (RIA). Intravitreal injection of cholinergic antagonists decreased the rate of depletion of LELI during the dark phase, suggesting the presence of cholinergic excitatory control of the LELI neurons. This cholinergic control involves nicotinic rather than muscarinic receptors, as tubocurarine appeared over 100 times more effective than atropine in inhibiting the decrease in retinal levels of LELI in the dark. (The ED50s were estimated at 3.2 and 450 nmol, respectively.) The lack of effect of the antagonists when applied during the light phase, suggest that there is little cholinergic input to the LELI amacrine cells in the light. Superfusing isolated retinas with buffer containing tubocurarine (10 microM) decreased the efflux of LELI by 35%, compared to the spontaneous release during the dark. Atropine (10 microM) had no effect on the release of LELI, and pilocarpine (100 microM) increased the release of LELI from retinas superfused in the light by 20%. We conclude that, in addition to previously reported glycinergic and dopaminergic inhibition, the LELI amacrine cells receive cholinergic excitatory input. A shift in balance between glycinergic and dopaminergic inhibitory, and cholinergic excitatory control may underly the light-driven variation in activity of the LELI neurons in chicken retina.
Boelen
M K
MK
Centre for Research on Ageing, La Trobe University College of Northern Victoria, Bendigo, Australia.
Dowton
M
M
Morgan
I G
IG
D000818:Animals; D001285:Atropine / Q000494:pharmacology; D002645:Chickens; D003624:Darkness; D004743:Enkephalin, Leucine / Q000037:antagonists & inhibitors / Q000378:metabolism*; D066298:In Vitro Techniques; D009538:Nicotine / Q000378:metabolism*; D010276:Parasympatholytics / Q000494:pharmacology; D010277:Parasympathomimetics / Q000494:pharmacology; D010862:Pilocarpine / Q000494:pharmacology; D011863:Radioimmunoassay; D012160:Retina / Q000166:cytology / Q000378:metabolism*; D014403:Tubocurarine / Q000494:pharmacology
D010276:Parasympatholytics; D010277:Parasympathomimetics; D010862:Pilocarpine; D004743:Enkephalin, Leucine; D009538:Nicotine; D001285:Atropine; D014403:Tubocurarine